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Purpose: The aims of this study were to investigate the efficacy of combining the systematized behavioral modification program 
(SBMP) with desmopressin therapy and to compare this with desmopressin monotherapy in the treatment of nocturnal poly-
uria (NPU).
Methods: Patients were randomized at 8 centers to receive desmopressin monotherapy (group A) or combination therapy, 
comprising desmopressin and the SBMP (group B). Nocturia was defined as an average of 2 or more nightly voids. The primary 
endpoint was a change in the mean number of nocturnal voids from baseline during the 3-month treatment period. The sec-
ondary endpoints were changes in the bladder diary parameters and questionnaires scores, and improvements in self-percep-
tion for nocturia. 
Results: A total of 200 patients were screened and 76 were excluded from the study, because they failed the screening process. A 
total of 124 patients were randomized to receive treatment, with group A comprising 68 patients and group B comprising 56 pa-
tients. The patients’ characteristics were similar between the groups. Nocturnal voids showed a greater decline in group B (−1.5) 
compared with group A (−1.2), a difference that was not statistically significant. Significant differences were observed between 
groups A and B with respect to the NPU index (0.37 vs. 0.29, P=0.028), the change in the maximal bladder capacity (−41.3 mL 
vs. 13.3 mL, P<0.001), and the rate of patients lost to follow up (10.3% [7/68] vs. 0% [0/56], P=0.016). Self-perception for noc-
turia significantly improved in both groups. 
Conclusions: Combination treatment did not have any additional benefits in relation to reducing nocturnal voids in patients 
with NPU; however, combination therapy is helpful because it increases the maximal bladder capacity and decreases the NPI. 
Furthermore, combination therapy increased the persistence of desmopressin in patients with NPU.
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INTRODUCTION
Nocturia severely affects a patient’s quality of life (QoL) [1]. Noc-
turia is associated with many factors, including nocturnal poly-
uria (NPU), detrusor overactivity, excessive fluid intakes, alcohol 
or caffeine consumption in the evening, inappropriate sleep hy-
giene, and a shortage of daily exercise [2-4]. Medications such as 
desmopressin, alpha-blockers, or anticholinergic agents are usu-
ally recommended for patients with nocturia, and desmopressin 
is usually the first therapeutic choice. Behavioral therapy and 
medication are the initial treatment options for patients with 
overactive bladders [5]. Nocturia is one of several storage symp-
toms, and behavioral modification is considered the initial treat-
ment option for patients with nocturia or NPU [2,6]. However, 
no standardized protocol has been established for the treatment 
of patients with NPU. 
 In a previous study, we demonstrated the efficacy of a system-
atized behavioral modification program (SBMP) in the absence 
of any medication [7]. We developed a 30-minute education 
program. In that study, we showed that education with 1 SBMP 
was sufficient for 78.5% of patients and that reinforcement edu-
cation was helpful for an additional 7.6% of patients with NPU. 
However, this SBMP has not been widely used in routine clinical 
practice, and no well-designed investigations have been under-
taken that have examined the efficacy of combination therapy 
that comprises desmopressin and the SBMP. 
 The aims of the present study were to compare the efficacy of 
combination therapy, comprising desmopressin and the SBMP, 
with desmopressin monotherapy in patients with NPU, and to 
demonstrate the most important factors that determine im-
provements in the QoL of patients with NPU. 
MATERIALS AND METHODS
Patients
Eligible patients included males and females who were aged 20 
years or more and who had nocturia and NPU. Nocturia was 
defined as an average of 2 or more nightly voids and was deter-
mined using a 3-day frequency-volume chart. NPU was defined 
as a nocturnal urine volume that was more than one-third of the 
total daily urine volume. Patients who were excluded from this 
study included those with diabetes insipidus, polydipsia with 
hyponatremia with a serum sodium level of less than 135 mmol/
L, urinary incontinence, urinary tract infections, indwelling 
catheters, planned pregnancies, surgical histories involving the 
prostate gland or urethra, and patients taking drugs known or 
suspected to interact with desmopressin, including diuretics, tri-
cyclic antidepressants, indomethacin, and carbamazepine. This 
trial was performed in accordance with the Declaration of Hel-
sinki, and the Institutional Review Board of Seoul National Uni-
versity (IRB 06-2012-19) approved the study. The ClinicalTrials.
gov Identifier is NCT01576900. All patients provided written in-
formed consent. 
Study Design
This was a prospective, multicenter, randomized parallel study 
that involved 8 centers. Using random number tables, patients 
were randomized 1:1 to receive 0.1 mg or 0.2 mg of desmopres-
sin monotherapy or a combination of desmopressin therapy and 
the SBMP. In a previous study [8], the response within each treat-
ment group was normally distributed with a standard deviation 
of 0.96. We used the value from this study because there were no 
previously published studies available that had investigated dif-
ferences between the SBMP and placebo-based behavioral ther-
apy in patients with NPU with respect to nocturnal voids. The 
true difference in the nocturnal voids was 0.44 [8]. The probabil-
ity of a type I error associated with testing this null hypothesis 
was 0.05, and we needed to study 74 subjects in each group to be 
able to reject the null hypothesis that the mean number of noc-
turnal voids within the desmopressin monotherapy and the 
combined therapy groups was equal to a probability of 0.8. The 
rate of patients lost to follow up was estimated at 25%. The final 
sample size was determined to be 100 cases in each group.
 The patients were advised to take desmopressin 1 hour before 
bedtime and to empty their bladders before they went to bed ev-
ery night. Patients were told to avoid drinking more than 200 
mL of water or other fluids. Any diuretics or caffeinated soft 
drinks were also prohibited in the evening. When a patient was 
assigned to the combination therapy group, desmopressin was 
prescribed and 1 SBMP was performed. The desmopressin was 
supplied by Ferring Pharmaceuticals (Saint-Prex, Switzerland).
 The patients visited the outpatient clinic for their initial screen-
ing assessments on week 1. The basic screening tests included 
assessing the patients’ current illnesses, taking their medical his-
tories, measuring their blood pressures, digital rectal examina-
tions for men, and laboratory tests that included prostate-specif-
ic antigen levels and prostate ultrasonography for men, electro-
lyte chemistry, urinalysis with microscopy, urine culture, human 
chorionic gonadotropin levels in the urine for women, and uro-
flowmetry with postvoid urine volumes. Three-day frequency-
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volume charts recorded 24-hour fluid intakes and urine produc-
tion, the times and volumes of the voids, bedtimes, and the times 
at which the patients rose. On week 3, the second visit to the 
outpatient clinic occurred, which involved patient randomiza-
tion and the prescription of desmopressin and SBMP education.
Dose Titration 
All patients initially received 0.2-mg desmopressin. Serum sodi-
um levels were checked before the patients were randomized 
and at every visit to the clinic. The desmopressin dose was re-
duced from 0.2 to 0.1 mg if sodium levels declined to less than 
135 mmol/L, or if the enrolled patients experienced intolerable 
adverse events (AEs). Desmopressin medication was stopped if 
the serum sodium level declined to less than 130 mmol/L, or if 
the patients refused to take the medication. 
Behavioral Therapy
Patients within the desmopressin monotherapy group were giv-
en brief explanations about the importance of fluid restriction 
after dinner during their appointments in the outpatient depart-
ment. Patients within the combination therapy group under-
went the SBMP that comprised a 30-minute education program 
[7]. During the education program, patients watched videos that 
explained the normal physiology underlying the process of urine 
formation and urination, and we explained the necessity of the 
behavioral modification program. We advised that 1,500 mL 
was the appropriate urine output volume, and that consuming 
caffeinated beverages or fluid-containing foods after dinner was 
prohibited. We provided specific guidance in relation to behav-
ioral patterns. We emphasized the importance of sleep hygiene. 
Finally, we checked the patients’ bladder diaries and gave feed-
back on these to improve the efficacy of the SBMP.
Study Endpoints
The primary endpoints were a change in the mean number of 
nocturnal voids and the proportion of 50% responders during 
the 3-month treatment period. A 50% responder was defined as 
a patient who experienced a decline of at least 50% in the mean 
number of nocturnal voids from baseline to the time of the final 
visit to the outpatient clinic. The secondary endpoints were 
changes in the bladder diary parameters, International Consul-
tation on Incontinence Questionnaire-Nocturia (ICIQ-N) scores, 
and nocturia quality-of-life (N-QoL) questionnaire scores, and 
improvements in self-perception for nocturia.
 Patients completed the ICIQ-N and the N-QoL question-
naire. Serum sodium levels were checked within 1 week of des-
mopressin being prescribed. The third and fourth visits to the 
outpatient clinic occurred after 1 and 3 months of treatment, 
respectively, following randomization. The patients completed 
3-day frequency-volume charts, the ICIQ-N, the N-QoL ques-
tionnaire, the patient perception of bladder condition (PPBC) 
questionnaire, and the global response assessment (GRA). The 
ICIQ were linguistically validated by bilingual translators and 
were approved for clinical use by the International Consultation 
on Incontinence Modular Questionnaire Advisory Board (http://
www.iciq.net/index.html). A high level of overall linguistic va-
lidity has been demonstrated in a previous investigation in as-
sociation with the N-QoL and the PPBC questionnaires [9].
 The variables associated with the frequency-volume chart 
were the nocturnal urine volumes (NUV), maximal bladder ca-
pacity (MBC), nocturia index, actual number of nightly voids, 
nocturnal polyuria index (NPI), and the nocturnal bladder ca-
pacity index (NBCI). 
Safety and Tolerability
Safety assessments were performed before the medication was 
prescribed and at the end of treatment, and they included the vi-
tal signs, physical examinations, body weights, and measurements 
of serum sodium levels. In the absence of any AE, patients were 
assigned to receive 0.2-mg desmopressin. If the patients experi-
enced any clinically significant AE, such as voiding difficulties, 
peripheral edema, or sodium levels that were lower than 135 
mmol/L, the desmopressin dose was reduced to 0.1 mg or discon-
tinued. All AEs were recorded at every clinic visit. 
Statistical Analysis
Descriptive data, including the patients’ characteristics, are pre-
sented. The treatment groups were compared in relation to the 
laboratory results and the clinical parameters using a stratified 
Cochran-Mantel-Haenszel test that controlled for age. A paired t-
test was performed to determine whether any differences arose as 
a consequence of adding the SBMP to the management of patients 
who were being prescribed desmopressin. A P-value of <0.05 was 
considered statistically significant. All statistical analyses were per-
formed using the SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). 
RESULTS
Patient Characteristics
In total, 200 patients (141 males and 59 females) were screened 
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to participate in the study at 8 centers. The mean (±standard de-
viation) age of the patients was 66.8 (±8.5) years. A total of 76 
patients were excluded from the study, because they fulfilled one 
or more of the exclusion criteria. As shown in Fig. 1, 124 patients 
entered the randomization and the dose-titration phases of the 
study, and they received at least 1 dose of desmopressin medica-
tion. Sixty-eight (54.8%) and 56 patients (45.2%) were random-
ized to receive either desmopressin monotherapy (group A) or 
combined therapy with desmopressin and the SBMP (group B), 
respectively. Seven patients in the desmopressin monotherapy 
group and none of the patients in the combined therapy group 
stopped the medication during the study period. The patients’ 
characteristics were similar in both study groups (Table 1), and 
the study completion rate was 89.7% for group A and 100% for 
group B (P=0.016). A significantly larger MBC was evident in 
the desmopressin monotherapy group compared with the com-
bination therapy group. 
Primary Endpoints
Nocturia improved significantly in both treatment groups. Noc-
turnal voids significantly declined from baseline to the end of 
the study (−1.32 ±1.39, P <0.001). The combination therapy 
group showed a greater decline in the number of nocturnal voids 
compared with the desmopressin monotherapy group, and the 
proportion of patients with a 50% reduction in the mean num-
ber of nocturnal voids was higher in the combination therapy 
group than in the desmopressin monotherapy group (Table 2). 
However, no statistically significant differences were evident be-
tween the treatment groups in relation to the number of noctur-
nal voids or the clinical response rates. There were no differences 
between the sexes with respect to the number of nocturnal voids 
or the clinical response rates. 
Secondary Endpoints
Changes in the N-QoL questionnaire scores showed that the 
scores associated with ‘a change of productivity the next day’ 
Fig. 1. Study design and disposition of patients. ICIQ-N, International Consultation on Incontinence Questionnaire-Nocturia; N-
QoL, nocturia quality of life; SBMP, systematized behavioral modification program; PPBC, patient perception of bladder condition; 
ITT, intention-to-treat; GRA, global response assessment.
Visit 0
200 Patients
• Nightly void≥2
• Nocturnal polyuria
56 Combination of desmopressin and SBMP ITT
Questionnaire (ICIQ-N, N-QoL, PPBC, GRA)
• 3-Day frequency-volume chart
62 Desmopressin monotherapy 
• 1 Discontinuation
• Questionnaire (ICIQ-N, N- QoL, PPBC, GRA)
• 3-Day frequency-volume chart
56 Combination of desmopressin and SBMP 
• 0 Discontinuation (n=0)
• Questionnaire (ICIQ-N, N-QoL, PPBC, GRA)
• 3-Day frequency-volume chart
Full analysis set: 124 patients into randomization
• 3-Day frequency-volume chart, questionnaires (ICIQ-N, N-QoL)
• 1st SBMP education
Visit 1
68 Desmopressin monotherapy ITT
Questionnaire (ICIQ-N, N-QoL, PPBC, GRA)
• 3-Day frequency-volume chart
Visit 2
Visit 3
6 Discontinuation
• 2 Adverse event
• 2 Lack of efficacy
• 2 Failure to return
1 Discontinuation
• 1 Lack of efficacy
61 Completed study 56 Completed study
0 Discontinuation
0 Discontinuation
76 Screening failure
www.einj.org    217
 Cho, et al.  •  Combination of Desmopressin and Behavioral Modification INJ
Int Neurourol J 2014;18:213-220
(question 4) and ‘concern of disturbing others in the house’ 
(question 8) were more significantly affected in the combination 
therapy group compared with the desmopressin monotherapy 
group. Self-perceived improvements were demonstrated in the 
PPBC and GRA scores; however, no statistically significant dif-
ferences were observed between the treatment groups with re-
spect to the PPBC and GRA scores. The bladder diary parame-
ters showed that only the NPI showed a significant difference 
between the treatment groups. When we analyzed the changes 
in each bladder diary parameter from the beginning of the study 
to the final visit to the outpatient clinic at the end of the study, a 
significant difference was observed between the desmopressin 
monotherapy group and the combination therapy group in rela-
tion to the change in the MBC (−41.3±96.3 mL vs. 13.3±37.9 
mL; P<0.001). None of these results showed any differences ac-
cording to sex.
 The SBMP increased the study completion rate in patients 
with nocturia. The rate of patients lost to follow up was 10.3% 
(7/68) and 0% (0/56) in the desmopressin monotherapy group 
and the combination therapy group, respectively (P=0.016). 
Table 1. Patient demographics and baseline characteristics
Variable
ITT population
P-value
Desmopressin (n=68) Combination (n=56)
Male 51 (75.0) 44 (78.6) 0.675
Age (yr) 67.0±8.2 (39.0–81.0) 66.5±8.9 (41.0–85.0) 0.738
Height (cm) 165.4±7.9 (148.0–180.0) 164.3±8.1 (143.0–183.0) 0.478
Body weight (kg) 65.8±70.5 (37.0–93.0) 65.3±9.7 (42.2–94.0) 0.790
Blood pressure_systolic (mm Hg) 124.3±11.0 (95.0–150.0) 122.9±10.2 (91.0–149.0) 0.454
Blood pressure_diastolic (mm Hg) 75.5±7.8 (51.0–92.0) 77.7±7.9 (54.0–97.0) 0.113
Comorbidity
   Hypertension 29 (42.6) 22 (39.3) 0.718
   Diabetes mellitus 15 (22.1) 11 (19.6) 0.826
Uroflowmetric parameters
   Maximal urine flow (mL/sec) 14.7±7.4 (5.3–39.7) 14.1±8.2 (5.1–45.1) 0.678
   Voided urine volume (mL) 188.5±113.2 (47.7–582.0) 168.1±88.3 (36.0–377.6) 0.331
   Postvoid residual urine (mL) 14.3±19.5 (0–89.0) 13.7±22.3 (0–99.0) 0.889
N-QoL questionnaires
   Total 44.4±8.1 (21.0–60.0) 41.5±9.0 (23.0–61.0) 0.062
   Subscores (sleep/energy) 22.1±5.3 (6–30) 20.5±6.2 (6.0–40.0) 0.141
   Subscores (bother/concern) 21.8±5.0 (11.0–34.0) 20.3±5.5 (11.0–33.0) 0.112
Voiding diary parameters
   24-Hour total urine volume (mL) 1,922.6±901.0 (870–6,450) 1,888.4±976.0 (567–6,510) 0.841
   Nocturnal urine volume (mL) 856.8±500.4 (345–3,570) 831.9±404.6 (200–2,850) 0.767
   Total number of nightly voids 2.5±1.1 (5–21) 2.8±1.2 (6–80) 0.141
   Maximal bladder capacity (mL) 360.3±105.2 (130–550) 319.7±105.1 (100–550) 0.036*
   Nocturia index 2.4±0.9 (0.7–6.6) 3.0±2.7 (1.3–20.0) 0.072
   Nocturnal polyuria index 0.4±0.1 (0.2–0.7) 1.3±5.4 (0.1–40.0) 0.242
   Nocturnal bladder capacity index 0.8±0.8 (0–3.7) 0.7±0.7 (0–3.0) 0.429
Values are presented as number (%) or mean±standard deviation (range).
ITT, intention-to-treat; N-QoL, nocturia quality of life.
*P<0.05, statistically significant.
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Adverse Events
A total of 11 patients (8.9%) showed AE, and none of the patients 
in either study group showed significant AE. There were 2 cases 
of dizziness and 1 case of facial flushes in the desmopressin 
monotherapy group. Each group contained 1 case of peripheral 
edema and 1 case of voiding difficulties that were not clinically 
significant. Hyponatremia occurred in 1 case in the desmopres-
sin monotherapy group and in 3 cases in the combination thera-
py group. Reducing the dose of desmopressin to 0.1 mg im-
proved hyponatremia in all cases. 
DISCUSSION
Although behavioral therapy has been shown to be safe and ef-
fective in the treatment of patients with NPU [7], a standardized 
treatment protocol has not yet been widely accepted because 
nocturia is associated with many factors, including NPU, detru-
sor overactivity, excessive fluid intakes, evening alcohol or caf-
Table 2. Responses to desmopressin and combination treatments
Variable
ITT population
P-value
Desmopressin (n=68) Combination (n=56)
Primary endpoints
   Nocturnal voids –1.18±1.37 (–3.0 to 1.0) –1.48 ±1.41 (–5 to 1) 0.227
Change in N-QoL questionnaires scores
   1. Difficult to concentrate the next day 0.89±1.29 (–3 to 4) 0.69±1.17 (–3 to 4) 0.354
   2. Feel low in energy the next day 0.80±1.19 (–2 to 4) 0.69±1.13 (–3 to 4) 0.592
   3. Nap during the day 0.64±1.07 (–2 to 3) 0.45±1.16 (–2 to 3) 0.337
   4. Less productive the next day 1.00±1.32 (–3 to 3) 0.46±1.05 (–2 to 4) 0.014*
   5. Participate less in activities I enjoy 0.57±1.36 (–3 to 2) 0.36±0.95 (–3 to 4) 0.325
   6. Careful about when or how much I drink 0.20±1.52 (–2 to 3) 0.31±1.12 (–4 to 4) 0.624
   7. Difficult to get enough sleep at night 1.45±2.41 (–2 to 4) 1.32±1.48 (–13 to 4) 0.720
   8. Disturbing others in the house 1.30±1.55 (–4 to 4) 0.45±1.42 (–2 to 4) 0.002*
   9. Preoccupied about having to get up 1.34±1.50 (–1 to 4) 1.21±1.39 (–2 to 4) 0.617
   10. Worried that this condition will get worse 1.39±1.46 (–2 to 4) 1.36±1.41 (–1 to 4) 0.894
   11. Worry about no effective treatment 1.11±1.64 (–3 to 4) 1.15±1.57 (–3 to 4) 0.885
   12. How bothersome has getting up at night –1.51±1.48 (–5 to 2) –1.61±1.42 (–4 to 2) 0.714
   13. Rating my quality of life to be –0.42±0.94 (–3 to 2) –0.47±0.95 (–4 to 1) 0.765
Patient perception of bladder condition 2.5±0.6 (1–3) 2.4±0.7 (1–3) 0.291
Global response assessment 5.8±1.3 (2–7) 6.0±1.0 (4–7) 0.447
Voiding diary parameters
   24-Hour total urine volume (mL) 1,587.0±1,025.9 (418–3,810) 1,444.2±460.0 (755–2,550) 0.352
   Nocturnal urine volume (mL) 483.7±301.3 (70–1,430) 423.8±244.8 (150–1,173) 0.251
   Total number of nightly voids 1.3±1.0 (4–14) 1.3±1.1 (5–15) 0.991
   Maximal bladder capacity (mL) 317.4±106.1 (120–550) 331.8±98.6 (90–550) 0.461
   Differences in maximal bladder capacity (mL) –41.3±96.3 (–380 to 250) 13.3±37.9 (–60 to 150) <0.001
   Nocturia index 1.54±0.87 (0.33–5.20) 1.54±1.01 (0.41–6.13) 0.985
   Nocturnal polyuria index 0.37±0.27 (0.08–1.45) 0.29±0.13 (0.11–0.68) 0.028*
   Nocturnal bladder capacity index 0.48±0.63 (–1.00 to 2.00) 0.52±0.76 (–1.00 to 2.33) 0.746
Values are presented mean±standard deviation (range).
ITT, intention-to-treat; N-QoL, nocturia quality of life.
*P<0.05, statistically significant.
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feine consumption, inappropriate sleep hygiene, and shortages 
of daily exercise [2-4]. Nocturia is one of several storage symp-
toms and it is usually associated with an overactive bladder. Al-
though behavioral modification therapy and medication are ini-
tial treatment options for patients with overactive bladders 
[5,10], behavioral modification therapy has not been widely 
used in routine clinical practice in patients with nocturia. While 
both desmopressin and behavioral therapy are effective in pa-
tients with NPU [7,11,12], there is little evidence that demon-
strates the efficacy of a combination of these treatments. To the 
best of our knowledge, this is the first investigation to show the 
efficacy of a combination of desmopressin and SBMP therapy, 
and to compare the efficacy of desmopressin and the SBMP in 
combination with desmopressin monotherapy in patients with 
NPU. 
 Although the authors performed the SBMP rigorously on the 
patients, there was no statistically significant difference between 
the treatment groups with respect to a decline in the number of 
nocturnal voids, which could be associated with several factors. 
First, the authors have previously demonstrated the efficacy of 
the SBMP after reinforcement SBMP education, if the latter was 
required [5]. However, the SBMP was only performed once in 
the present study. Second, combination therapy with the SBMP 
may become less effective when primary treatment with desmo-
pressin is very effective in the treatment of NPU. This suggests 
that clinicians should be aware of the necessity for repetitive 
SBMP education for patients with NPU, and that they should 
consider the patients’ baseline characteristics, the severity of the 
NPU, and drug persistence.
 However, desmopressin treatment in combination with the 
SBMP was more beneficial than desmopressin monotherapy in 
the management of patients with NPU. The analysis of the N-
QoL questionnaires showed that changes in the scores for ‘pro-
ductivity the next day’ (question 4) and ‘concern of disturbing 
others in the house’ (question 8) were more significant in the 
combination therapy group than in the desmopressin monother-
apy group. Additionally, the rate of patients lost to follow up was 
10.3% (7/68) in the desmopressin monotherapy group and it was 
0% (0/56) in the combination therapy group, which means that 
the SBMP increased the study completion rate and/or the per-
sistence of desmopressin in patients with nocturia. These results 
imply that the SBMP significantly affected the daily lives of the 
patients with NPU and that the patients started to take an active 
interest in their oral intakes and urine production. 
 The analysis of the bladder diary parameters suggested that 
the results from the present study were attributable to increases 
in the MBC and decreases in the NPI. The baseline MBC was 
higher in the desmopressin monotherapy group than in the com-
bination therapy group. While there was no difference between 
the groups with respect to the MBC at the final outpatient visits, 
the study findings demonstrated differences in the MBC be-
tween the first and the last outpatient clinic visits, which would 
mean the comparative results of increase or decrease in the MBC 
between the groups. A previous study investigated the efficacy 
and safety of desmopressin in patients with mixed nocturia [12] 
and it showed reductions in the mean number of nocturnal 
voids, NUV, NPI, and NBCI. The authors of this study also ex-
plained that the effect of desmopressin on patients with mixed 
nocturia was mainly attributable to improvements in the MBC. 
This suggests that behavioral therapy and the resultant decrease 
in the number of nocturnal voids increases the efficiency of blad-
der emptying during sleep. 
 There are several limitations to the present study that are de-
scribed next. First, the number of patients who failed the screen-
ing assessments was high (38%; 76/200 patients). Second, the 
mean number of nocturnal voids was low, which means that the 
additional effect of the SBMP would have been greater in patients 
with severe nocturia. Third, we did not perform a urodynamic 
study to differentiate the mixed type of NPU with detrusor over-
activity [10]. Fourth, the starting dose of desmopressin was 0.2 
mg in the present study, which might help to explain why com-
bining desmopressin treatment with the SBMP did not show 
any significant additional beneficial effects. However, the authors 
thought that it was better to choose a conservative methodology 
to determine whether SBMP treatment combined with desmo-
pressin therapy had a beneficial effect on patients compared 
with desmopressin monotherapy. Fifth, our previous investiga-
tion showed that education with 1 SBMP was sufficient for 78.5% 
of patients and that reinforcement education with SBMP was 
helpful for an additional 7.6% of patients with nocturia [7]. Re-
inforcement SBMP might have shown a significant beneficial ef-
fect in the group that received combination therapy compared 
with the group that received desmopressin therapy alone; how-
ever, we considered that the satisfaction rate from 1 SBMP was 
not low, and that we needed to simplify the study design to de-
termine the effect of desmopressin and SBMP therapy in combi-
nation compared with desmopressin administered alone. 
 In conclusion, desmopressin monotherapy and the combina-
tion of desmopressin with the SBMP reduced the number of 
nocturnal voids. Combination therapy did not have any addi-
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tional benefits in relation to reducing the number of nocturnal 
voids in patients with NPU. However, combined desmopressin 
and SBMP therapy was associated with an increase in the MBC 
and a decrease in the NPI when it was administered to patients 
with NPU. Furthermore, combination therapy increased the 
study completion rate and the persistence of desmopressin in 
patients with NPU.
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